Vial (Drug Discovery) Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
169
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$10M
- Investors
-
8
Vial (Drug Discovery) General Information
Description
Operator of a biotech company intended to reimagine drug development by building for hyper-scale. The company advances programs into the clinic powered by dramatically cheaper trials and computationally designed therapeutics, enabling biotechnology companies to deploy into different trial phases and partner with clinics to increase their revenue.
Contact Information
Website
vial.comCorporate Office
- 1050 Battery Street
- Suite 150
- San Francisco, CA 94111
- United States
Corporate Office
- 1050 Battery Street
- Suite 150
- San Francisco, CA 94111
- United States
Vial (Drug Discovery) Timeline
Vial (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Debt - General | 18-Jun-2025 | $10M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B2) | 30-Nov-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 21-Sep-2021 | $34.8M | $42M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | $7.2M | $7.2M | Completed | Startup |
Vial (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 10,191,420 | $0.000010 | 6% | $0.08 | $0.08 | 1x | $0.08 | 3.74% |
| Series A | 14,645,350 | $0.000010 | 6% | $0.41 | $0.41 | 1x | $0.41 | 5.37% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vial (Drug Discovery) Comparisons
Industry
Financing
Details
Vial (Drug Discovery) Competitors (7)
One of Vial (Drug Discovery)’s 7 competitors is Imaging Endpoints, a Corporation company based in Scottsdale, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Imaging Endpoints | Corporation | Scottsdale, AZ | ||||
| Parexel International | Private Equity-Backed | Raleigh, NC | ||||
| CTI Clinical Trial and Consulting | Private Equity-Backed | Covington, KY | ||||
| Syneos Health | Private Equity-Backed | Morrisville, NC | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA |
Vial (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vial (Drug Discovery) Patents
Vial (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260317433-A1 | Anti-interleukin-4 receptor alpha antibodies and uses thereof | Pending | 01-Nov-2024 | ||
| US-20260242497-A1 | Antibodies and polypeptides comprising variant fc regions | Pending | 17-Apr-2024 | ||
| WO-2025221933-A1 | Antibodies and polypeptides comprising variant fc regions | Pending | 17-Apr-2024 | ||
| WO-2025221933-A9 | Antibodies and polypeptides comprising variant fc regions | Pending | 17-Apr-2024 | A61P37/00 |
Vial (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vial (Drug Discovery) Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ATEL Capital Group | Asset Manager | Minority | ||
| Buckley Ventures | Venture Capital | Minority | ||
| Byers Capital Investment Advisory | Family Office | Minority | ||
| General Catalyst | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Vial (Drug Discovery) FAQs
-
When was Vial (Drug Discovery) founded?
Vial (Drug Discovery) was founded in 2020.
-
Where is Vial (Drug Discovery) headquartered?
Vial (Drug Discovery) is headquartered in San Francisco, CA.
-
What is the size of Vial (Drug Discovery)?
Vial (Drug Discovery) has 169 total employees.
-
What industry is Vial (Drug Discovery) in?
Vial (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Vial (Drug Discovery) a private or public company?
Vial (Drug Discovery) is a Private company.
-
What is Vial (Drug Discovery)’s current revenue?
The current revenue for Vial (Drug Discovery) is .
-
How much funding has Vial (Drug Discovery) raised over time?
Vial (Drug Discovery) has raised $119M.
-
Who are Vial (Drug Discovery)’s investors?
ATEL Capital Group, Buckley Ventures, Byers Capital Investment Advisory, General Catalyst, and are 5 of 8 investors who have invested in Vial (Drug Discovery).
-
Who are Vial (Drug Discovery)’s competitors?
Imaging Endpoints, Parexel International, CTI Clinical Trial and Consulting, Syneos Health, and Charles River Laboratories International are some of the 7 competitors of Vial (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
